(AMIX) Autonomix Medical Common - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05330T2050
AMIX: Microchips, Sensors, Catheters, Implants
Autonomix Medical, Inc. (NASDAQ:AMIX) is a development-stage medical device company specializing in advancing technologies for the sensing and treatment of peripheral nervous system disorders. The companys proprietary platform features a catheter-based, microchip-enabled sensing array designed to detect and differentiate neural signals with high precision. This technology holds potential for addressing a range of clinical applications, including pancreatic cancer, chronic pain management, hypertension, and cardiovascular conditions. Autonomix has entered into a strategic collaboration with NoiseFigure Research, Inc. to further develop its next-generation microchip technology. Founded in 2014 and headquartered in The Woodlands, Texas, the company remains focused on R&D initiatives aimed at improving outcomes for patients with nerve-related disorders. Web URL: https://autonomix.com
Based on the provided data, Autonomix Medical, Inc. (AMIX) is expected to remain under pressure in the near term. The stock is trading below its 20-day and 50-day moving averages, with the 200-day moving average significantly higher at 12.58, indicating a bearish trend. The average trading volume of 23,450 shares over the past 20 days suggests limited liquidity, which could exacerbate volatility. The ATR of 0.24 reflects moderate price movement. On the fundamental side, the companys market cap of $5.99M and P/B ratio of 0.62 suggest it is operating with a smaller valuation and may face challenges in scaling its operations. While the companys focus on innovative medical technologies could provide long-term upside, the lack of earnings and revenue growth may continue to weigh on the stock in the short term. Over the next three months, AMIX is likely to remain range-bound with potential downside risks unless the company announces significant progress in its development pipeline or partnerships.
Additional Sources for AMIX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AMIX Stock Overview
Market Cap in USD | 6m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2024-01-29 |
AMIX Stock Ratings
Growth 5y | -53.3% |
Fundamental | -31.0% |
Dividend | 0.0% |
Rel. Strength Industry | -96.6 |
Analysts | 5/5 |
Fair Price Momentum | 2.04 USD |
Fair Price DCF | - |
AMIX Dividends
No Dividends PaidAMIX Growth Ratios
Growth Correlation 3m | -82% |
Growth Correlation 12m | -96% |
Growth Correlation 5y | -97% |
CAGR 5y | -96.90% |
CAGR/Max DD 5y | -0.99 |
Sharpe Ratio 12m | -1.07 |
Alpha | -89.27 |
Beta | -2.85 |
Volatility | 180.61% |
Current Volume | 23.1k |
Average Volume 20d | 22.8k |
As of March 14, 2025, the stock is trading at USD 2.05 with a total of 23,100 shares traded.
Over the past week, the price has changed by -18.00%, over one month by -28.07%, over three months by -35.74% and over the past year by -96.58%.
Probably not. Based on ValueRay Fundamental Analyses, Autonomix Medical Common (NASDAQ:AMIX) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -30.98 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AMIX as of March 2025 is 2.04. This means that AMIX is currently overvalued and has a potential downside of -0.49%.
Autonomix Medical Common has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy AMIX.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AMIX Autonomix Medical Common will be worth about 2.2 in March 2026. The stock is currently trading at 2.05. This means that the stock has a potential upside of +7.32%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 18 | 778% |
Analysts Target Price | 28 | 1265.9% |
ValueRay Target Price | 2.2 | 7.3% |